Blog
RSS FeedPosted by Michael Wonder on 04 Sep 2017
Statistical and clinical significance
4 September 2017 - In published research, a statistically significant result is often wrongly interpreted as representing a clinically important ...
Posted by Michael Wonder on 02 May 2017
Addressing bias and conflict of interest among biomedical researchers
2 May 2017 - Bias in research is ubiquitous and the goal of every researcher should be to reduce bias and ...
Posted by Michael Wonder on 07 Mar 2017
Defining the non-inferiority margin and analysing non-inferiority: an overview
6 March 2017 - Non-inferiority trials are used to assess whether the effect of a new drug is not worse than ...
Posted by Michael Wonder on 20 Feb 2017
Big pharma funding biases drug trials in favour of a sponsor's product: review
21 February 2017 - Drug and device trial studies that are sponsored by the pharmaceutical industry are more likely to ...
Posted by Michael Wonder on 18 Jan 2017
Pharmaceutical industry financial ties linked to 'positive' outcomes in clinical trials for new drugs
18 January 2017 - A new study has found links between medical researchers' financial ties with pharmaceutical companies and "positive" ...
Posted by Michael Wonder on 30 Nov 2016
South Australia to commence PrEP trials
30 November 2016 - The South Australian Premier Jay Wetherill has announced people at high risk of contracting HIV will ...
Posted by Michael Wonder on 11 Oct 2016
Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals
7 October 2016 - Academic researchers from the UK have assessed the adequacy of reporting of non-inferiority trials alongside the ...
Posted by Michael Wonder on 19 Sep 2016
Real-world evidence: a comparison of the Australian Herceptin Program and clinical trials of trastuzumab for HER2-positive metastatic breast cancer
19 September 2016 - Estimating the real-world cost-effectiveness of a new drug relies on understanding the differences between clinical trial data ...